FDA Challenges Nereus TV Ad's Safety Claims

Viewers who see the ad should confirm driving and timing warnings in the full prescribing information.

Updated on Nov. 5, 2026 in Alzheimer’s

FDA Challenges Nereus TV Ad's Safety Claims

The FDA has sent Vanda Pharmaceuticals an untitled letter alleging that its Nereus television advertisement misstates the drug's safety and effectiveness. Vanda must respond in writing within 15 working days of the October 26, 2026 letter.

Why it matters

FDA untitled letters flag advertising that may leave viewers with an inaccurate picture of a medication's risks, which matters for anyone weighing a drug based on a commercial. The agency's concern centers on whether the ad's visuals undercut the driving-impairment warning that is central to safe use.

The FDA reviewed the Nereus advertisement and concluded it fails to present the major statement concurrently in audio and text, and that its storyline and visual style interfere with viewers' comprehension of that statement. The agency's findings are regulatory conclusions about the ad, not clinical trial results.

The players

Vanda Pharmaceuticals

A drug company whose treatment areas include sleep and psychiatric disorders, and which markets Nereus.

U.S. Food and Drug Administration

The federal agency responsible for regulating prescription drug labeling and advertising to protect public health.

The details

The FDA says the animated ad depicts a car chase through a Mediterranean-style town and along a coastal road, then shows the man taking a pill before boarding a motorboat. The ad creates the impression that Nereus can be taken after or immediately before activities that could induce vomiting, even though the drug is taken as a preventive measure 60 minutes beforehand. The driving-impairment warning that Nereus may impair physical or mental abilities needed to drive is voiced during the coastal road scene, and the FDA ruled that the visuals of driving conflict with that warning.

Timeline

  1. October 26, 2026: FDA sends Vanda the untitled letter about the Nereus ad.

  2. 15 working days after October 26, 2026: Vanda's deadline to respond to the FDA in writing.

Health Landscape

The FDA's untitled letter process addresses promotional material that departs from required risk disclosures without rising to the level of a formal warning letter. Oversight of drug advertising like this shapes how consumers encounter risk information for prescription medicines across the country.

If you or a family member is considering Nereus, the ad's driving-impairment warning is a reason to read the full prescribing information, not only the commercial. Worth discussing with your doctor are the drug's timing instructions and any effect on driving or daily activities.

The takeaway

Drug advertisements can leave out or obscure important risk information, so the full product label is the most reliable source. Confirm dosing timing and any driving or activity warnings with your physician before making decisions about a medication.

What happens next

Vanda Pharmaceuticals must respond to the FDA in writing within 15 working days of the October 26, 2026 letter.

Further reading

For more on how drug companies and regulators approach medication risk information, see our coverage in Alzheimer’s.

Source note: This article includes information reported by FiercePharma.